Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis.
BACKGROUND
Joint immobilisation improves the therapeutic effect of intra-articular glucocorticoid injection for knee synovitis. This may be due to retarded steroid resorption by immobilisation, a procedure that also could influence cartilage and bone metabolism.


OBJECTIVE
To evaluate changes in cartilage and bone turnover after intra-articular glucocorticoid treatment for knee synovitis with and without postinjection rest.


METHODS
20 patients with rheumatoid arthritis and knee synovitis were randomised to 24 hour bed rest or to normal activity after intra-articular glucocorticoid treatment. Serum and urine markers of cartilage and bone turnover were studied for two weeks. Cartilage oligomeric matrix protein (COMP) was used as a marker of cartilage turnover, osteocalcin as marker of bone formation, and deoxipyridinoline (DPD) as marker of bone resorption.


RESULTS
After the glucocorticoid injection COMP levels decreased in both groups (p<0.001), but significantly more in resting patients. Serum osteocalcin levels decreased significantly (p<0.001) without any difference between the groups. DPD was unchanged in both groups.


CONCLUSIONS
Intra-articular glucocorticoid treatment for knee synovitis reduced serum COMP, which suggests that such treatment may have a cartilage protective effect. The slightly larger decrease of serum COMP in the resting group may reflect a lower clearance of COMP from the joint cavity. Serum osteocalcin was temporarily reduced, indicating a reversible suppression of bone formation.
Weitoft
T
T
Section of Rheumatology, Department of Internal Medicine, Gävle Hospital, 801 87 Gävle, Sweden. tomas.weitoft@lg.se
Larsson
A
A
Saxne
T
T
Rönnblom
L
L
D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000378:metabolism; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001510:Bed Rest; D015415:Biomarkers / Q000378:metabolism; D016723:Bone Remodeling / Q000187:drug effects*; D001862:Bone Resorption / Q000503:physiopathology; D064236:Cartilage Oligomeric Matrix Protein; D002358:Cartilage, Articular / Q000187:drug effects* / Q000378:metabolism; D016326:Extracellular Matrix Proteins / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D007270:Injections, Intra-Articular; D007719:Knee Joint / Q000378:metabolism; D008297:Male; D064235:Matrilin Proteins; D008875:Middle Aged; D015675:Osteocalcin / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects; D013585:Synovitis / Q000188:drug therapy / Q000503:physiopathology; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
D000596:Amino Acids; D018501:Antirheumatic Agents; D015415:Biomarkers; D064236:Cartilage Oligomeric Matrix Protein; D016326:Extracellular Matrix Proteins; D005938:Glucocorticoids; D006023:Glycoproteins; D064235:Matrilin Proteins; C577553:TSP5 protein, human; D015675:Osteocalcin; C036020:deoxypyridinoline; D014222:Triamcinolone Acetonide